华蟾素制剂在肿瘤患者的临床使用分析

doi:10.19803/j.1672-8629.20240298

摘要/Abstract

摘要： 目的分析住院肿瘤患者使用华蟾素制剂的应用特点,为华蟾素制剂的合理使用提供参考。方法采用PASSPharmAssist 系统调取潍坊市人民医院 2020 年1月1日至 2023 年 8 月31日使用华蟾素制剂的住院患者数据，使用 Excel 2016软件对人口学特征、诊断信息和具体使用情况进行统计分析。结果共纳入463例患者，使用华蟾素制剂629例次，调查发现肿瘤患者中男性[平均年龄（63.00±9.70）岁，57.02%]多于女性[平均年龄（59.11±10.83）岁，42.98%]，平均年龄（61.31±10.37）岁，涉及前5位癌症种类为肺癌（44.45 %）、结直肠癌（28.94%）、胃癌（9.51%）、食管癌（4.10%）、肝癌（3.02%），华蟾素制剂主要用药方案为联合化疗方案（36.57%），存在与免疫检查点抑制剂、靶向药物、镇痛药物以及放疗等方式联合应用230例，其中77例（33.48%）未出现ADR，119例（51.74%）为一般ADR，34例（14.78%）为严重ADR。临床实际应用中存在剂量过大的情况，用药疗程主要集中在10 d以内。结论华蟾素制剂主要用于肺癌以及消化道癌化疗前和化疗时用药，目前其临床疗效和作用机制需进一步验证和阐明，缺乏用药疗程的统一资料，应警惕剂量过大引发的心脏毒性。

关键词: 华蟾素, 肺癌, 结直肠癌, 胃癌, 食管癌, 肝癌, 肿瘤, 化疗

Abstract: Objective To conduct a retrospective study of usage of cinobufagin preparations in hospitalized tumor patients in order to provide reference for rational use of cinobufagin. Method The PASSPharmaAssist system was used to retrieve data of patients from Weifang People’s Hospital who used cinobufagin preparations between 1 January, 2020 and 31 August, 2023. The demographic data, diagnostic information, and usage were statistically analyzed using Excel 2016 software. Results A total of 463 patients were enrolled, and 629 cases of the use of cinobufagin preparations. The survey found that among tumor patients, males [with an average age of (63.00 ± 9.70) years, accounting for (57.02%)] outnumbered females [with an average age of (59.11 ± 10.83) years, accounting for (42.98%)], with an average age of (61.31 ± 10.37) years. The top five types of cancers involved were lung cancer (44.45%), colorectal cancer (28.94%), gastric cancer (9.51%), esophageal cancer (4.10%), and liver cancer (3.02%), The dominating medication regimens involving cinobufagin were combined chemotherapy (36.57%). In addition, there were cases of combined use with immune checkpoint inhibitors, targeted drugs, analgesics and radiotherapy (230 cases). Among them, 77 cases (33.48%) had no ADR, 119 cases (51.74%) were general ADR and 34 cases (14.78%) were serious ADR. In clinical practice, there was excessive dosage, and the courses of medication were mostly less than 10 days. Conclusion Cinobufagin is primarily used in the treatment of lung cancer and gastrointestinal cancer, especially before and during chemotherapy. The clinical efficacy and mechanism of action remain to be verified and elucidated, and there is still a lack of consensus on the course of medication. It is necessary to be vigilant against cardiac toxicity caused by excessive doses.

Key words: cinobufagin, lung cancer, colorectal cancer, gastric cancer, esophageal cancer, liver cancer, cancer, chemotherapy

中图分类号:

周秀丽, 刘宝生, 马文明, 汪琪, 王杨, 赵世鹏. 华蟾素制剂在肿瘤患者的临床使用分析[J]. 中国药物警戒, 2024, 21(7): 791-797.

ZHOU Xiuli, LIU Baosheng, MA Wenming, WANG Qi, WANG Yang, ZHAO Shipeng. Clinical use of cinobufagin preparations in cancer patients[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 791-797.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240298

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I7/791

参考文献

[1] Chronic Non communicable Disease Prevention and Control Center of China Center for Disease Control and Prevention. China Cause of Death Surveillance Dataset (中国死因监测数据集)[M]. Beijing: China Science and Technology Press, 2021.
[2] LI WB.Research on the epidemic status, disease burden, and time trends of malignant tumors in Nanchang City from 2017 to 2021[D]. Nanchang: Nanchang University, 2023.
[3] ZHANG KL, SI WT, SHAO HM, et al.Application of traditional Chinese medicine treatment in adverse reactions of tumor chemotherapy[J]. Chinese Medicine Emergency(中国中医急症), 2015, 24(7): 1212-1214.
[4] ZHANG J, HONG Y, XIE P, et al.Spatial lipidomics reveals anticancer mechanisms of bufalin in combination with cinobufagin in tumor-bearing mice[J]. Front Pharmacol, 2021, 11: 593815.
[5] MIN SD, WANG YU.Research progress on the anti-tumor mechanism of cinobufacin[J]. Journal of Traditional Chinese Medicine(中医药学报), 2022, 50(11): 96-101.
[6] ZHOU B, WU F, YUAN L, et al.Is cinobufacin beneficial in treating advanced non-small-cell lung cancer? Evidence from a meta-analysis of its efficacy combined with chemotherapy[J]. Evid Based Complement Alternat Med, 2015: 2015, 408145.
[7] YE YQ, LI QL, ZHU YD, et al.Research progress on the anti-tumor mechanism of Cinobufacin[J]. Pharmacology and Clinics of Chinese Materia Medica(中药药理与临床), 2022, 38(3): 215-220.
[8] BA XY, ZHOU SY, LUO XX.Research progress on the pharmacological effects and mechanisms of cinobufacin on anti-cancer pain[J]. Chinese Journal of Pain Medicine(中国疼痛医学杂志), 2019, 25(9): 695-698.
[9] ZHENG R, ZHANG S, ZENG H, et al.Cancer incidence and mortality in China, 2016[J]. Journal of the National Cancer Center, 2022, 2(1): 1-9.
[10] CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[11] CHEN MH, LIU T, SU YX, et al.Analysis of the efficacy and safety of different doses of cinobufotalin injection combined with chemotherapy in the treatment of advanced lung cancer[J]. Chinese Remedies & Clinics(中国药物与临床), 2020, 20(19): 3241-3243.
[12] HAN LY.Study on the chemistry, metabolism, activity and toxicity of bufotoxin ligands in cinobufacin[D]. Beijing: Institute of Traditional Chinese Medicine, Chinese Academy of Traditional Chinese Medicine, 2018.
[13] MENG Q, YAU LF, LU JG, et al.Chemical profiling and cytotoxicity assay of bufadienolides in toad venom and toad skin[J]. Ethnopharmacol, 2016, 187: 74-82.
[14] LI M, LI H, WANG XJ, et al.Research progress on the cardiotoxicity of toad venom[J]. Chin J Pharm Toxicol(中国药理学与毒理学杂志), 2016, 30(5): 605-610.
[15] ZHANG YL, JIAO LJ, XU L.Progress in clinical treatment mode of traditional Chinese medicine combined with chemotherapy for lung cancer[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2021, 36(4): 2222-2224.
[16] XU C, WU QB.Advances in the clinical study of cinobufacini for non-small cell lung cancer[J]. Chinese Medical Herald(中国医药导报), 2017, 23(17): 100-103.
[17] LUO C, GAO B, BIAN B, et al.Systematic review of cinobufacini injection for lung cancer[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2016, 22(8): 208-214.
[18] LIN MY, LIU YF, ZOU QF, et al.Meta-analysis of cinobufotalin injection combined therapy on advanced non-small cell lung cancer[J]. China Medicine and Pharmacy(中国医药科学), 2022,12(20): 58-62.
[19] FENG GQ.The effect of Cinobufagin capsules on immune function and quality of life in postoperative chemotherapy patients with lung cancer[J]. Clinical Research(临床研究), 2021, 29(2): 115-117.
[20] HUANG RC, SU YH.Clinical efficacy of Cinobufacin capsules combined with chemotherapeutic drugs in the treatment of non-small cell lung cancer: a meta-analysis[J]. Clinical Medication Journal(临床药物治疗杂志), 2018, 16(5): 59-63.
[21] ZHANG C, SONG YX, GUI YX.Value of cinobufacini capsule combined with chemotherapy in the treatment of advanced lung[J]. Journal of Practical Traditional Chinese Internal Medicine(实用中医内科杂志), 2022, 36(1): 102-104.
[22] CAI YL, ZHENG J, ZHANG JH, et al.Cinobufotalin - mediated miR-497 -5p/VEGFA pathway regulates proliferation, apoptosis and angiogenesis of lung cancer cells[J]. Journal of Modern Oncology(现代肿瘤医学), 2023, 31(4): 632-637.
[23] ZHANG LL, HUANG XL, GUO T, et al.Study of cinobufagin as a promising anticancer agent in uveal melanoma through intrinsic apoptosis pathway[J]. Front Oncol, 2020(10): 325.
[24] ZHANG GX, WANG C, SUN M, et al.Cinobufagin inhibits tumor growth by inducing intrinsic apoptosis through AKT signaling pathway in human nonsmall cell lung cancer cells[J]. Oncotarget, 2016, 7(20): 28935-28946.
[25] CAO YF, YU L, DAI G, et al.Cinobufagin induces apoptosis of osteosarcoma cells through inactivation of Notch signaling[J]. Eur J Pharmacol, 2017, 794: 77-84.
[26] DENG X, SHENG J X, LIU H, et al.Cinobufagin promotes cell cycle arrest and apoptosis to block human esophageal squamous cell carcinoma cells growth via the p73 signalling pathway[J]. Biological & Pharmaceutical Bulletin, 2019, 42(9): 1500-1509.
[27] YANG T, SHI R L, CHANG L, et al.Cinobufacin suppresses human bladder cancer cell growth through the Fas / Fasl and TNF- alpha/ TNFR1 pathway in vitro and in vivo[J]. J Exp Clin Cancer Res, 2015, 34(1): 21.
[28] XUE R, ZHANG QS, ZHANG YJ, et al.Anti tumor effect and mechanism of cinobufagin on nude mice bearing breast cancer MCF-7[J]. Practical Pharmacy and Clinical Remedies(实用药物与临床), 2014, 17(7): 815-817.
[29] SHI YL, CHOU JS, CHEN YL, et al.Bufalin enhances immune responses in leukemic mice through enhancing phagocytosis of macrophage in vivo[J]. In vivo(Athens,Greece), 2018, 32(5): 1129-1136.
[30] YE MJ, WU XH, CHEN SY, et al. Association between epithelial-mesenchymal transition and the vegfa/vegfr2 autocrine pathway in human hepatocellular carcinoma huh7 cells and the regulatory effect of cinobufagin[J/OL]. Journal of Anhui University of Chinese Medicine(安徽中医药大学学报),(2024-05-08)[2024-06-16]. http://229.208.102:8085/kcms/detail/34.1324.R.20240508.1550.002.html.
[31] HUANG JH, CHEN H, CHENG Y, et al.Efficacy and safety of patients with non-small cell lung cancer treated with anlotinib combined with cinobufagin[J]. Systems Medicine(系统医学), 2024, 9(7): 54-57.
[32] YANG QW, PENG SL.Clinical effect and safety of XELOX regimen combined with Huachansu capsule in the treatment of advanced colorectal cancer[J]. Clinical Research and Practice(临床医学研究与实践), 2021, 6(12):36-38.
[33] LI L, HUANG YJ, ZENG JN.Effectiveness and safety of cinobufacini combined with chemotherapy in the treatment of colorectal cancer: a meta-analysis[J]. Journal of Chengde Medical University(承德医学院学报), 2022, 39(2): 91-95.
[34] LI HX, YOU WB, CHEN L, et al.Study on the anti-tumor mechanism of cinobufacin-induced AMPK phosphorylation to promote immunogenic apoptosis of colorectal cancer cells[J]. Chin J Mod Appl Pharm(中国现代应用药学), 2021, 38(21) : 2659-2664.
[35] LU XS, QIAO YB, LI Y, et al.Preclinical study of cinobufagin as a promising anti-colorectal cancer agent[J]. Oncotarget, 2017, 8(1): 988-998.
[36] BAI Y, WANG XY, CAI MS, et al.Cinobufagin suppresses colorectal cancer growth via STAT3 pathway inhibition[J]. Am J Cancer Res, 2021, 11(1): 200-214.
[37] LI X W, CHEN C H, DAI Y, et al.Cinobufagin suppresses colorectal cancer angiogenesis by disrupting the endothelial mammalian target of rapamycin /hypoxia-inducible factor 1α axis[J]. Cancer Sci, 2019, 110(5): 1724-1734.
[38] KUAI QY, CHENG Y, ZHANG Y, et al.Effect and mechanism of cinobufotalin against gastrointestinal malignant tumors:a review[J]. Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2023, 29(5): 264-271.
[39] HUANG ZY, CHEN MQ, QIAN FY.The clinical effects for the patients with NSCLC by radiotherapy combine with Hua Chan tablets[J]. Chinese Medical and Pharmacy(中国医药科学), 2014, 4(19): 156-158.
[40] ZHU BS, TIAN HA, SHU CR, et al.Clinical efficacy of Huachansu combined with radiotherapy in the treatment of advanced pancreatic cancer[J]. China Medicine(中国医药),2020, 15(5): 749-752.
[41] BAI XH, WEI Y, LI WB, et al.Effect of SOX chemotherapy regimen combined with cinobufotalin tablets in the treatment of patients with advanced gastric cancer and its influences on immune, inflammatory indexes and tumor markers levels[J]. Clinical Research and Practice(临床医学研究与实践), 2024, 9(11): 49-53.
[42] CHEN YH, HAO L.Observation of the effect of adjuvant application of cinobufagin during postoperative radiotherapy and chemotherapy for laryngeal cancer[J]. Journal of Modern Integrated Traditional Chinese and Western Medicine(现代中西医结合杂志), 2018, 27(12): 1307-1310.
[43] YUAN JQ, GUO Y.Meta analysis of the efficacy and safety of cinobufagin combined with three-step analgesic method in the treatment of cancer pain[J]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine(浙江中西医结合杂志), 2023, 33(2): 168-177.
[44] CAO SY, REN WF, FANG ZH, et al.A case of drug-induced liver injury caused by cinobufacini capsules[J]. Chin J Mod Appl Pharm(中国现代应用药学), 2022, 39(4): 542-543.
[45] CHEN K.Research on prescription optimization and rational application of traditional Chinese patent medicines and simple preparations participated by pharmacists in tumor hospitals[J]. Journal of Traditional Chinese Medicine Management(中医药管理杂志), 2024, 32(8): 74-76.
[46] LIU XD, ZHANG ZX, LIU XC, et al.Research progress of antitumor signaling pathway of cinobufagin[J]. Guangming Journal of Chinese Medicine(光明中医), 2024, 39(10): 2105-2108.
[47] WANG M, LI Y, LI S, et al.Cinobufacini injection delays hepatocellular carcinoma progression by regulating lipid metabolism via SREBP1 signaling pathway and affecting macrophage polarization[J]. J Ethnopharmacol, 2024, 321: 117472.
[48] DENG YQ, GAO M, LU D, et al.Compound-composed Chinese medicine of Huachansu triggers apoptosis of gastric cancer cells through increase of reactive oxygen species levels and suppression of proteasome activities[J]. Phytomedicine, 2024 , 123: 155169.